Stauber R E, Mischinger H J, Trauner M, Pristautz H
Medizinische Universitätsklinik, Graz.
Acta Med Austriaca. 1993;20(3):57-60.
Orthotopic liver transplantation for hepatic neoplasms is controversial. In the past, liver transplantation was utilized to treat various advanced hepatic neoplasms such as hepatocellular carcinoma including the fibrolamellar variant, cholangiocellular carcinoma, epithelioid hemangio-endothelioma, and liver metastases. In many cases, total hepatectomy with orthotopic liver replacement is the only treatment option with intent to cure because of reduced liver function in cirrhotic patients limiting resectability. On the other hand, results of transplantation are poor; for hepatocellular carcinoma, the 5-year-survival probability averages only 20%. Thus, hepatic neoplasms have to compete with benign liver diseases for a limited supply of donor organs. However, success rates of liver transplantation were higher for fibrolamellar carcinoma and for epithelioid hemangioendothelioma. New treatment strategies for hepatocellular carcinoma including neoadjuvant chemotherapy and chemoembolization are currently being investigated. Results of liver transplantation for cholangiocellular carcinoma or hepatic metastases have been disappointing. Single cases have been successfully treated with the "cluster operation" designed by Starzl in 1988.
肝脏肿瘤的原位肝移植存在争议。过去,肝移植被用于治疗各种晚期肝脏肿瘤,如肝细胞癌(包括纤维板层样变型)、胆管细胞癌、上皮样血管内皮瘤以及肝转移瘤。在许多情况下,由于肝硬化患者肝功能下降限制了可切除性,原位肝置换的全肝切除术是唯一有望治愈的治疗选择。另一方面,移植效果不佳;对于肝细胞癌,5年生存率平均仅为20%。因此,肝脏肿瘤必须与良性肝脏疾病竞争有限的供体器官供应。然而,纤维板层样癌和上皮样血管内皮瘤的肝移植成功率较高。目前正在研究肝细胞癌的新治疗策略,包括新辅助化疗和化疗栓塞。胆管细胞癌或肝转移瘤的肝移植结果令人失望。1988年,Starzl设计的“集群手术”成功治疗了个别病例。